磷酸奥司他韦
磷酸奥司他韦结构式
|
常用名 | 磷酸奥司他韦 | 英文名 | Oseltamivir phosphate |
|---|---|---|---|---|
| CAS号 | 204255-11-8 | 分子量 | 410.400 | |
| 密度 | 1.08g/cm3 | 沸点 | 473.3ºC at 760 mmHg | |
| 分子式 | C16H31N2O8P | 熔点 | 196-198°C | |
| MSDS | N/A | 闪点 | 240ºC |
|
A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.
PLoS ONE 10(3) , e0118780, (2015) Ferrets are the preferred animal model to assess influenza virus infection, virulence and transmission as they display similar clinical symptoms and pathogenesis to those of humans. Measures of disease severity in the ferret include weight loss, temperature r... |
|
|
Simvastatin modulates cellular components in influenza A virus-infected cells.
Int. J. Mol. Med. 34(1) , 61-73, (2014) Influenza A virus is one of the most important health risks that lead to significant respiratory infections. Continuous antigenic changes and lack of promising vaccines are the reasons for the unsuccessful treatment of influenza. Statins are pleiotropic drugs... |
|
|
Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
Drug Metab. Dispos. 42(9) , 1522-31, (2014) Hydrolysis plays an important role in metabolic activation of prodrugs. In the current study, species and in vitro system differences in hepatic and extrahepatic hydrolysis were investigated for 11 prodrugs. Ten prodrugs in the data set are predominantly hydr... |
|
|
In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4.
PLoS ONE 10(3) , e0121662, (2015) Our lead iminosugar analog called UV-4 or N-(9-methoxynonyl)-1-deoxynojirimycin inhibits activity of endoplasmic reticulum (ER) α-glucosidases I and II and is a potent, host-targeted antiviral candidate. The mechanism of action for the antiviral activity of i... |
|
|
Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
J. Virol. 89(10) , 5419-26, (2015) Human infections by avian influenza A(H7N9) virus entail substantial morbidity and mortality. Treatment of infected patients with the neuraminidase (NA) inhibitor oseltamivir was associated with emergence of viruses carrying NA substitutions. In the NA inhibi... |
|
|
The administration of oseltamivir results in reduced effector and memory CD8+ T cell responses to influenza and affects protective immunity.
FASEB J. 29(3) , 973-87, (2015) The clinical benefits of oseltamivir (Tamiflu) are well established, but the effects of antiviral treatment on the immune response are poorly understood. By use of flow cytometric analyses and the mouse model, we thoroughly investigated the impact of such a t... |
|
|
Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates.
Antiviral Res. 111 , 60-8, (2014) Influenza virus is a global health concern due to its unpredictable pandemic potential. Frequent mutations of surface molecules, hemagglutinin (HA) and neuraminidase (NA), contribute to low efficacy of the annual flu vaccine and therapeutic resistance to stan... |
|
|
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact.
J. Antimicrob. Chemother. 69(9) , 2458-69, (2014) The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly transmissible virus. Prior to the pandemic, many cou... |
|
|
An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.
J. Infect. Dis. 210(3) , 435-40, (2014) Human infections caused by avian influenza A virus type subtype H7N9 have been associated with substantial morbidity and mortality. Emergence of virus variants carrying markers of decreased susceptibility to neuraminidase inhibitors was reported. Here we show... |